surmount-1 tirzepatide weight loss percent nejm 2022 🔴Tirzepatide as Compared with Semaglutide for the Treatment of Obesity⤵️ @ 🔹Among participants with obesity but without diabetes, treatment with was superior to treatment with semaglutide with respect to reduction in Zepbound Clinical Trial Results: SURMOUNT-1

Semaglutide (Ozempic/Wegovy) Powerful GLP-1 receptor agonist, substantial weight loss (10-15%), already FDA approved for weight loss as Wegovy

Rotate the injection sites to minimize irritation and improve medication absorption

Getting your hormones balanced with help the efficacy of these peptides without a doubt and NOT having your hormones balanced will likely mean youll have a harder time with them working for you

Tirzepatide carries an FDA boxed warning about thyroid C-cell tumors based on rodent studies, but the relevance to humans is unknown

Early results from the REDEFINE-4 trial showed that participants lost an average of 22.7% of their body weight, making it a potential competitor to existing treatments

Multiple studies confirm that creatine is well-tolerated by most people and may even support longevity through its effects on mitochondrial health